BELLUS Health (BLU) Stock Price, News & Analysis

Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$19.48 to C$19.48
• 52-Week Range: N/A
• Volume: 28,666 shs
• Average Volume: 59,471 shs
• Market Capitalization: C$2.47 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BLU Stock Analysis - Frequently Asked Questions

How do I buy shares of BELLUS Health?

Shares of BLU stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Advanced Micro Devices (AMD), Algonquin Power & Utilities (AQN), BCE (BCE), Canadian Natural Resources (CNQ) and Nutrien (NTR).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:BLU
• CIK: N/A
• Web: www.bellushealth.com
• Phone: +1-450-6804500
• Fax: N/A
• Employees: 74
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-86,790,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.76%
• Return on Assets: -16.70%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 33.42
• Quick Ratio: 16.40

Sales & Book Value

• Annual Sales: C$16,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 4.67
• Book Value: C$2.91 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,810,000
• Free Float: N/A
• Market Cap: C$2.47 billion
• Optionable: Not Optionable
• Beta: -0.28